Cargando…

Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature

BACKGROUND: Albeit the need for sex-disaggregated results of adverse events after immunization (AEFIs) is gaining attention since the COVID-19 pandemic, studies with emphasis on sexual dimorphism in response to COVID-19 vaccination are relatively scarce. This prospective cohort study aimed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Duijster, Janneke W., Lieber, Thomas, Pacelli, Silvia, Van Balveren, Leontine, Ruijs, Loes S., Raethke, Monika, Kant, Agnes, Van Hunsel, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922710/
https://www.ncbi.nlm.nih.gov/pubmed/36793715
http://dx.doi.org/10.3389/fimmu.2023.1078736
_version_ 1784887584621592576
author Duijster, Janneke W.
Lieber, Thomas
Pacelli, Silvia
Van Balveren, Leontine
Ruijs, Loes S.
Raethke, Monika
Kant, Agnes
Van Hunsel, Florence
author_facet Duijster, Janneke W.
Lieber, Thomas
Pacelli, Silvia
Van Balveren, Leontine
Ruijs, Loes S.
Raethke, Monika
Kant, Agnes
Van Hunsel, Florence
author_sort Duijster, Janneke W.
collection PubMed
description BACKGROUND: Albeit the need for sex-disaggregated results of adverse events after immunization (AEFIs) is gaining attention since the COVID-19 pandemic, studies with emphasis on sexual dimorphism in response to COVID-19 vaccination are relatively scarce. This prospective cohort study aimed to assess differences in the incidence and course of reported AEFIs after COVID-19 vaccination between males and females in the Netherlands and provides a summary of sex-disaggregated outcomes in published literature. METHODS: Patient reported outcomes of AEFIs over a six month period following the first vaccination with BioNTech-Pfizer, AstraZeneca, Moderna or the Johnson&Johnson vaccine were collected in a Cohort Event Monitoring study. Logistic regression was used to assess differences in incidence of ‘any AEFI’, local reactions and the top ten most reported AEFIs between the sexes. Effects of age, vaccine brand, comorbidities, prior COVID-19 infection and the use of antipyretic drugs were analyzed as well. Also, time-to-onset, time-to-recovery and perceived burden of AEFIs was compared between the sexes. Third, a literature review was done to retrieve sex-disaggregated outcomes of COVID-19 vaccination. RESULTS: The cohort included 27,540 vaccinees (38.5% males). Females showed around two-fold higher odds of having any AEFI as compared to males with most pronounced differences after the first dose and for nausea and injection site inflammation. Age was inversely associated with AEFI incidence, whereas a prior COVID-19 infection, the use of antipyretic drugs and several comorbidities were positively associated. The perceived burden of AEFIs and time-to-recovery were slightly higher in females. DISCUSSION: The results of this large cohort study correspond to existing evidence and contribute to the knowledge gain necessary to disentangle the magnitude of the effect sex in response to vaccination. Whilst females have a significant higher probability of experiencing an AEFI than males, we observed that the course and burden is only to a minor extent different between the sexes.
format Online
Article
Text
id pubmed-9922710
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99227102023-02-14 Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature Duijster, Janneke W. Lieber, Thomas Pacelli, Silvia Van Balveren, Leontine Ruijs, Loes S. Raethke, Monika Kant, Agnes Van Hunsel, Florence Front Immunol Immunology BACKGROUND: Albeit the need for sex-disaggregated results of adverse events after immunization (AEFIs) is gaining attention since the COVID-19 pandemic, studies with emphasis on sexual dimorphism in response to COVID-19 vaccination are relatively scarce. This prospective cohort study aimed to assess differences in the incidence and course of reported AEFIs after COVID-19 vaccination between males and females in the Netherlands and provides a summary of sex-disaggregated outcomes in published literature. METHODS: Patient reported outcomes of AEFIs over a six month period following the first vaccination with BioNTech-Pfizer, AstraZeneca, Moderna or the Johnson&Johnson vaccine were collected in a Cohort Event Monitoring study. Logistic regression was used to assess differences in incidence of ‘any AEFI’, local reactions and the top ten most reported AEFIs between the sexes. Effects of age, vaccine brand, comorbidities, prior COVID-19 infection and the use of antipyretic drugs were analyzed as well. Also, time-to-onset, time-to-recovery and perceived burden of AEFIs was compared between the sexes. Third, a literature review was done to retrieve sex-disaggregated outcomes of COVID-19 vaccination. RESULTS: The cohort included 27,540 vaccinees (38.5% males). Females showed around two-fold higher odds of having any AEFI as compared to males with most pronounced differences after the first dose and for nausea and injection site inflammation. Age was inversely associated with AEFI incidence, whereas a prior COVID-19 infection, the use of antipyretic drugs and several comorbidities were positively associated. The perceived burden of AEFIs and time-to-recovery were slightly higher in females. DISCUSSION: The results of this large cohort study correspond to existing evidence and contribute to the knowledge gain necessary to disentangle the magnitude of the effect sex in response to vaccination. Whilst females have a significant higher probability of experiencing an AEFI than males, we observed that the course and burden is only to a minor extent different between the sexes. Frontiers Media S.A. 2023-01-30 /pmc/articles/PMC9922710/ /pubmed/36793715 http://dx.doi.org/10.3389/fimmu.2023.1078736 Text en Copyright © 2023 Duijster, Lieber, Pacelli, Van Balveren, Ruijs, Raethke, Kant and Van Hunsel https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Duijster, Janneke W.
Lieber, Thomas
Pacelli, Silvia
Van Balveren, Leontine
Ruijs, Loes S.
Raethke, Monika
Kant, Agnes
Van Hunsel, Florence
Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature
title Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature
title_full Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature
title_fullStr Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature
title_full_unstemmed Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature
title_short Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature
title_sort sex-disaggregated outcomes of adverse events after covid-19 vaccination: a dutch cohort study and review of the literature
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922710/
https://www.ncbi.nlm.nih.gov/pubmed/36793715
http://dx.doi.org/10.3389/fimmu.2023.1078736
work_keys_str_mv AT duijsterjannekew sexdisaggregatedoutcomesofadverseeventsaftercovid19vaccinationadutchcohortstudyandreviewoftheliterature
AT lieberthomas sexdisaggregatedoutcomesofadverseeventsaftercovid19vaccinationadutchcohortstudyandreviewoftheliterature
AT pacellisilvia sexdisaggregatedoutcomesofadverseeventsaftercovid19vaccinationadutchcohortstudyandreviewoftheliterature
AT vanbalverenleontine sexdisaggregatedoutcomesofadverseeventsaftercovid19vaccinationadutchcohortstudyandreviewoftheliterature
AT ruijsloess sexdisaggregatedoutcomesofadverseeventsaftercovid19vaccinationadutchcohortstudyandreviewoftheliterature
AT raethkemonika sexdisaggregatedoutcomesofadverseeventsaftercovid19vaccinationadutchcohortstudyandreviewoftheliterature
AT kantagnes sexdisaggregatedoutcomesofadverseeventsaftercovid19vaccinationadutchcohortstudyandreviewoftheliterature
AT vanhunselflorence sexdisaggregatedoutcomesofadverseeventsaftercovid19vaccinationadutchcohortstudyandreviewoftheliterature